ARS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	70.97	210.52	60.06	386.92	10.53	20.91
Short-Term Investments	157.39	63.86	0	0	0	0
Cash & Cash Equivalents	228.36	274.38	60.06	386.92	10.53	20.91
Cash Growth	-16.77%	356.82%	-84.48%	3575.84%	-49.66%	-
Other Current Assets	3.37	3.32	0.67	3.74	0	-0.13
Total Current Assets	231.73	277.7	60.73	390.66	10.53	20.78
Property, Plant & Equipment	0.82	0.77	0.69	3.8	4.57	6.02
Other Long-Term Assets	0.64	2.96	0.02	0.35	0.55	0.75
Total Long-Term Assets	1.46	3.74	0.72	4.15	5.12	6.77
Total Assets	233.19	281.44	61.45	394.8	15.65	27.55
Accounts Payable	2.15	4.93	3.11	2.58	3.52	0.78
Deferred Revenue	0	0.28	1.46	0	0	0
Current Debt	0.24	0.23	3.62	1.74	12.3	3.53
Other Current Liabilities	0	0	0	5.28	2.11	0.84
Total Current Liabilities	2.39	5.44	8.19	9.6	17.93	5.14
Long-Term Debt	0.04	0.25	5.41	2.33	3.32	4.21
Other Long-Term Liabilities	0	2.85	3.08	0	0	0
Total Long-Term Liabilities	0.04	3.11	8.49	2.33	3.32	4.21
Total Liabilities	2.43	8.55	16.68	11.93	21.25	9.35
Total Debt	0.27	0.48	9.03	4.07	15.62	7.73
Debt Growth	-43.04%	-94.68%	122.16%	-73.97%	101.97%	-
Retained Earnings	-131.3	-76.94	-42.26	-96.73	-63.79	-39.82
Comprehensive Income	0.05	0.41	0	0	0	0
Shareholders' Equity	230.76	272.89	-31.27	382.88	-58.78	-34.98
Net Cash / Debt	228.09	273.9	51.03	382.85	-5.09	13.18
Net Cash / Debt Growth	-16.73%	436.74%	-86.67%	-	-	-
Net Cash Per Share	2.40	6.86	1.77	131.68	-7.71	21.82
Working Capital	229.34	272.26	52.54	381.06	-7.4	15.63
Book Value Per Share	2.42	6.83	-1.08	131.68	-88.94	-57.93

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).